NCT07719933Completed
Intraoperative Continuous Terlipressin Infusion is Associated With Reduced Severe Postoperative Complications After Laparoscopic Hepatectomy: a Prospective Propensity Score-matched Cohort Study
Source: ClinicalTrials.gov · Last updated 28 Jul 2026
Brief summary (registry, in English)
Liver resection is an important surgical treatment for patients with liver diseases. Despite advances in surgical and anesthetic management, postoperative complications remain a major concern and may affect patient recovery. Maintaining stable blood circulation during surgery is an important part of perioperative care. Terlipressin is a vasoactive medication that may help maintain blood pressure and improve hemodynamic stability during surgery. However, the relationship between intraoperative continuous terlipressin infusion and postoperative outcomes after laparoscopic hepatectomy remains unclear. This prospective observational cohort study aims to evaluate the association between continuous intraoperative terlipressin infusion and postoperative severe complications in patients undergoing laparoscopic hepatectomy. Patients undergoing laparoscopic hepatectomy at the First Affiliated Hospital of Sun Yat-sen University will be enrolled and followed according to a predefined study protocol. Perioperative clinical information, anesthetic management data, terlipressin exposure, and postoperative outcomes will be collected and analyzed. The primary outcome is the occurrence of severe postoperative complications, defined as Clavien-Dindo grade III or higher complications.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 161 (actual)
- First submitted
- 18 Jul 2026
- Start date
- 1 Apr 2024
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07719933
What you commit to
- Study type: Observational
- Participants enrolled: 161
- From 1 Apr 2024 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Inability to tolerate the planned surgical procedure based on pre-anesthetic assessment
Other illness
- Significant cardiovascular or cerebrovascular disease, including active coronary artery disease, severe valvular stenosis, hypertrophic obstructive cardiomyopathy, or history of extensive cerebral infarction
- Known allergy to study medications
- Any other condition considered inappropriate for study participation by the investigator
Lab values
- Severe renal dysfunction (blood urea nitrogen \> 9 mmol/L or serum creatinine \> 178 μmol/L)
- Hemoglobin level \< 90 g/L
Other
- Severe hepatic dysfunction (Child-Pugh class B or higher)
- Body mass index (BMI) \> 35 kg/m² or \< 18 kg/m²
- Pregnancy or lactation
- Participation in another clinical trial within the preceding 3 months
Who the study is looking for
- Adults aged 18 to 80 years
- American Society of Anesthesiologists (ASA) physical status I-III
- Scheduled for elective laparoscopic partial hepatectomy
- Provided written informed consent
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| the First Affiliated Hospital of Sun Yat-sen University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.